NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

And, just look at all the glowing replies to Senti’s somewhat impressive post. Not a one out of step!


The P value, whether it .02 or .05, will likely be nonsensical
at this point. No accounting for initial inclusion / exclusion criteria. If it’s found surviving patients went on to other treatments or the Expanded Access “arm” who failed initial inclusion criteria are figured in the tld, for better or for worse, the SC / FDA may just be making a Go-no-go decision based on a multitude of external factors.